Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Inclusion Criteria:

   - Documentation of IgAN diagnosis established on kidney biopsy obtained any time prior
   to or during the Screening Period.

   - UPCR ≥ 0.75 g/g or UP ≥1 g/day from the mean of two 24-hour urine collections during
   Screening.

   - Estimated GFR ≥ 30 mL/min/1.73 m2 at Screening.

   - Exploratory Cohort: eGFR 20-29 mL/min/1.73 m2 at Screening. A kidney biopsy is
   required within 6 months prior to Screening or during the Screening Period.

   - Presence of hematuria as defined by a positive result on urine dipstick for blood or ≥
   5 red blood cells (RBCs)/high power field microscopy on urine sediment during or
   within 3 months of Screening.

   - Stable and maximum allowed or tolerated RASI (ACEI and/or ARB) dose for ≥ 3 months
   prior to Screening with no planned change during Screening through Week 106.

   - Participants who are on an SGLT2I, ERA, or MRA must be on a stable and maximum allowed
   or tolerated dose for ≥ 3 months prior to Screening with no planned change through
   Week 106.

Exclusion Criteria:

   - Diagnosis of rapid progressive glomerulonephritis as measured by eGFR loss ≥ 50% over
   a period of 3 months prior to Screening.

   - Secondary IgAN (eg, due to systemic lupus erythematosus (SLE), cirrhosis, or celiac
   disease).

   - Concomitant clinically significant renal disease other than IgAN.

   - Prior use of immunosuppressive treatment for IgAN within 6 months of screening.

   - Uncontrolled diabetes mellitus with glycosylated hemoglobin (HbA1c) > 8.5%.

   - Clinically active Henoch-Schonlein purpura (IgA vasculitis) requiring ongoing systemic
   immunosuppressive therapy at Screening.

   - History of kidney transplant or planned kidney transplant during the Treatment Period.

   - Splenectomy or functional asplenia.

   - History of Neisseria meningitidis infection.

   - Active systemic bacterial, viral, or fungal infection within 14 days prior to
   randomization.